

Daniel A Goldstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6263528/publications.pdf>

Version: 2024-02-01

91
papers

2,252
citations

249298

26
h-index

274796

44
g-index

91
all docs

91
docs citations

91
times ranked

3762
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 532-540.	1.0	14
2	Subcutaneous Atezolizumab: A Jab Without a Benefit. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 134-135.	0.8	1
3	Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial Toxicity. <i>JAMA Oncology</i> , 2022, 8, 821.	3.4	3
4	Health Disparities in Prostate Cancer and Approaches to Advance Equitable Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 360-365.	1.8	3
5	The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2021, 99, 555-561.	0.9	13
6	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021, 39, 950-955.	0.8	28
7	Registration trials in countries without access to US standards of care – pitfalls of interpretation. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 395-396.	12.5	1
8	Factors associated with off-label (OL) drug use in oncology: The role of cost and financing in a universal healthcare system.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18825-e18825.	0.8	0
9	Prospects of off-label (OL) drug use in oncology: Identifying predicting variables for registration and universal healthcare reimbursement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18842-e18842.	0.8	0
10	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021, 4, 396-404.	2.6	30
11	Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. <i>Health Economics (United Kingdom)</i> , 2021, 30, 699-707.	0.8	57
12	Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. <i>Frontiers in Pharmacology</i> , 2021, 12, 754390.	1.6	3
13	Combination therapy patents: a new front in evergreening. <i>Nature Biotechnology</i> , 2021, 39, 1504-1510.	9.4	8
14	Should every candidate for cataract extraction be scheduled to the preoperative clinic? The Rabin Medical Center experience. <i>European Journal of Ophthalmology</i> , 2020, 30, 1268-1271.	0.7	5
15	Transitional Cell Carcinoma and Pseudocirrhosis – A Case Report and Review of the Literature. <i>Journal of Gastrointestinal and Abdominal Radiology</i> , 2020, 3, S73-S76.	0.2	0
16	Interventional Pharmacoeconomics. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 330-334.	1.0	8
17	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab – Letter. <i>Clinical Cancer Research</i> , 2020, 26, 2435-2435.	3.2	2
18	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1769-1777.	1.1	25

#	ARTICLE	IF	CITATIONS
19	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. <i>Cancer Medicine</i> , 2020, 9, 4603-4612.	1.3	3
20	Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. <i>JAMA Oncology</i> , 2020, 6, 1694.	3.4	29
21	Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer. <i>Immunotherapy</i> , 2020, 12, 235-243.	1.0	17
22	Mature Versus Registration Studies of Immuno-Oncology Agents: Does Value Improve With Time?. <i>JCO Oncology Practice</i> , 2020, 16, e779-e790.	1.4	3
23	Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions. <i>Head and Neck</i> , 2020, 42, 1713-1720.	0.9	3
24	Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 487-493.	2.3	33
25	The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States. <i>Clinical Colorectal Cancer</i> , 2019, 18, 209-217.	1.0	6
26	Alternative dosing regimens for atezolizumab: right dose, wrong frequency. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1153-1155.	1.1	20
27	Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987830.	1.4	16
28	Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment. <i>JAMA Oncology</i> , 2019, 5, 1097.	3.4	43
29	Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 5.	0.6	40
30	A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate-to Poor-Risk Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 366-371.	1.9	26
31	The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	22
32	Patient-Centered Oncology or Population-Centered Oncology—Which Do We Want, and Which Tradeoffs Are We Willing To Accept?. <i>Oncologist</i> , 2019, 24, 288-290.	1.9	0
33	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478.	1.9	25
34	Association Between Reimbursement Incentives and Physician Practice in Oncology. <i>JAMA Oncology</i> , 2019, 5, 893.	3.4	28
35	The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer. <i>JAMA Oncology</i> , 2018, 4, 623.	3.4	17
36	Early Steps in the Value of Cancer Care—Many Paths Remain Unexplored. <i>Oncologist</i> , 2018, 23, 391-392.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. <i>JAMA Oncology</i> , 2018, 4, 326.	3.4	43
38	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. <i>Lung Cancer</i> , 2018, 126, 217-223.	0.9	89
39	Denosumab for bone lesions in multiple myeloma – what is its value?. <i>Haematologica</i> , 2018, 103, 753-754.	1.7	13
40	Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. <i>European Urology</i> , 2018, 74, 57-62.	0.9	56
41	Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1700-1709.	0.6	28
42	A Policy That Encourages Wastage of Expensive Medications – The JW Modifier. <i>JAMA Oncology</i> , 2018, 4, 155.	3.4	5
43	Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2018, 73, 628-634.	0.9	57
44	Time Is Money: Optimizing the Scheduling of Nivolumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 3074-3076.	0.8	42
45	Trajectories of Injectable Cancer Drug Costs After Launch in the United States. <i>Journal of Clinical Oncology</i> , 2018, 36, 319-325.	0.8	80
46	Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib – A cost-effectiveness analysis. <i>PLoS ONE</i> , 2018, 13, e0207132.	1.1	38
47	Duration of adjuvant immunotherapy – biologic, clinical and economic considerations. <i>Medical Oncology</i> , 2018, 35, 160.	1.2	9
48	Information Transparency in the Drug Approval Process – Reply. <i>JAMA Oncology</i> , 2018, 4, 1622.	3.4	0
49	A real-world analysis of cancer drug wastage due to oversized vials. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 643-646.	0.7	10
50	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework – Reply. <i>JAMA Oncology</i> , 2018, 4, 1438.	3.4	1
51	Weight-based dosing vs fixed dosing of pembrolizumab: an economic analysis. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 549-551.	0.3	1
52	Financial toxicity in cancer care – Edging toward solutions. <i>Cancer</i> , 2017, 123, 1301-1302.	2.0	23
53	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	0.8	89
54	Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. <i>Oncologist</i> , 2017, 22, 623-625.	1.9	23

#	ARTICLE	IF	CITATIONS
55	A Pharmacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	76
56	Adjuvant Ipilimumab for Melanoma—The \$1.8 Million per Patient Regimen. <i>JAMA Oncology</i> , 2017, 3, 1628.	3.4	13
57	Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. <i>Oncologist</i> , 2017, 22, 694-699.	1.9	27
58	Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?. <i>Cancer</i> , 2017, 123, 3872-3874.	2.0	4
59	A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. <i>Oncotarget</i> , 2017, 8, 71548-71555.	0.8	90
60	Reply to A. Benedict et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 3086-3087.	0.8	1
61	Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 513-523.	0.6	12
62	Using Quality-Adjusted Life-Years in Cost-Effectiveness Analyses: Do Not Throw Out the Baby or the Bathwater. <i>Journal of Oncology Practice</i> , 2016, 12, 500-502.	2.5	5
63	Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. <i>Lung Cancer</i> , 2016, 98, 114-117.	0.9	127
64	The cost and value of cancer drugs—are new innovations outpacing our ability to pay?. <i>Israel Journal of Health Policy Research</i> , 2016, 5, 40.	1.4	18
65	Opposition to Value-Based Cancer Care—Interests of Patients or Conflicts of Interest?. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1842-1843.	1.4	0
66	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016, 33, 48.	1.2	20
67	The Ethical and Practical Challenges of Value-Based Cancer Care at the Patient's Bedside. <i>JAMA Oncology</i> , 2016, 2, 860.	3.4	4
68	Successful Robotic Excision and Early Chemotherapy for Primary Cardiac Lymphoma. <i>Annals of Thoracic Surgery</i> , 2016, 102, 304-305.	0.7	4
69	Economics of ramucirumab for metastatic colorectal cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 733-745.	0.7	3
70	Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. <i>Annals of Pharmacotherapy</i> , 2016, 50, 712-717.	0.9	15
71	Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World. <i>Oncologist</i> , 2016, 21, 907-909.	1.9	13
72	Understanding the value of cancer drugs—the devil is in the detail. <i>Cancer</i> , 2016, 122, 2292-2295.	2.0	4

#	ARTICLE	IF	CITATIONS
73	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. <i>Clinical Colorectal Cancer</i> , 2016, 15, 1-6.	1.0	72
74	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016, 42, 10-17.	3.4	16
75	Perspectives in Oncology Drug Pricing—Reply. <i>JAMA Oncology</i> , 2016, 2, 402.	3.4	0
76	Global differences in cancer drug prices: A comparative analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA6500-LBA6500.	0.8	6
77	Global differences in cancer drug prices: A comparative analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA6500-LBA6500.	0.8	7
78	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3842-3843.	0.8	0
79	First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States—Based Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1112-1118.	0.8	144
80	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	3.4	43
81	Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2015, 20, 981-982.	1.9	26
82	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3727-3732.	0.8	86
83	Metastatic colorectal cancer in a cirrhotic liver with synchronous hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2015, 3, 321.	0.7	1
84	Costs and effectiveness of genomic testing in the management of colorectal cancer. <i>Oncology</i> , 2015, 29, 175-83.	0.4	16
85	Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective. <i>American Journal of Managed Care</i> , 2015, 21, S234-41.	0.8	0
86	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 477-486.	1.0	0
87	Dermato-Neuro Syndrome in a Patient Treated With Autologous Stem Cell Transplant for Scleromyxedema. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e213-e215.	0.2	11
88	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 219-225.	1.0	35
89	Mesenchymal Precursor Cells as Adjunctive Therapy in Recipients of Contemporary Left Ventricular Assist Devices. <i>Circulation</i> , 2014, 129, 2287-2296.	1.6	139
90	Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. <i>Cancer Prevention Research</i> , 2013, 6, 428-436.	0.7	65

#	ARTICLE	IF	CITATIONS
91	International health in medical education: students' experiences and views. <i>Journal of Health Organization and Management</i> , 2007, 21, 575-579.	0.6	9